154 related articles for article (PubMed ID: 29969659)
1. IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells.
Notarangelo T; Sisinni L; Trino S; Calice G; Simeon V; Landriscina M
Cancer Lett; 2018 Oct; 433():147-155. PubMed ID: 29969659
[TBL] [Abstract][Full Text] [Related]
2. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
3. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.
Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
Exp Cell Res; 2020 May; 390(2):111942. PubMed ID: 32173467
[TBL] [Abstract][Full Text] [Related]
4. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
[TBL] [Abstract][Full Text] [Related]
5. Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAF
Wang K; Li Y; Song N; Che X; Hou K; Xu L; Bai M; Wang Q; Wang Y; Zhou Y; Cao M; Liu Y; Zhang J
J Cell Biochem; 2019 Apr; 120(4):5315-5325. PubMed ID: 30320916
[TBL] [Abstract][Full Text] [Related]
6. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).
Xing J; Liu R; Xing M; Trink B
Biochem Biophys Res Commun; 2011 Jan; 404(4):958-62. PubMed ID: 21185263
[TBL] [Abstract][Full Text] [Related]
7. Combination Treatment with the BRAF
Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
[TBL] [Abstract][Full Text] [Related]
9. Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells.
Notarangelo T; Sisinni L; Condelli V; Landriscina M
Cancer Cell Int; 2017; 17():86. PubMed ID: 29033690
[TBL] [Abstract][Full Text] [Related]
10. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
11. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.
Herr R; Halbach S; Heizmann M; Busch H; Boerries M; Brummer T
Oncogene; 2018 Mar; 37(12):1576-1593. PubMed ID: 29326440
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition.
Zhi J; Zhang P; Zhang W; Ruan X; Tian M; Guo S; Zhang W; Zheng X; Zhao L; Gao M
J Clin Endocrinol Metab; 2021 Jan; 106(1):91-107. PubMed ID: 32936899
[TBL] [Abstract][Full Text] [Related]
13. Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways.
Dang H; Sui M; He Q; Xie J; Liu Y; Hou P; Ji M
Int J Biol Macromol; 2023 Sep; 248():125867. PubMed ID: 37473892
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
[TBL] [Abstract][Full Text] [Related]
15. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
Salerno P; De Falco V; Tamburrino A; Nappi TC; Vecchio G; Schweppe RE; Bollag G; Santoro M; Salvatore G
J Clin Endocrinol Metab; 2010 Jan; 95(1):450-5. PubMed ID: 19880792
[TBL] [Abstract][Full Text] [Related]
16. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
Liu R; Liu D; Xing M
J Clin Endocrinol Metab; 2012 Feb; 97(2):E173-82. PubMed ID: 22090271
[TBL] [Abstract][Full Text] [Related]
17. Vitamin C sensitizes BRAF
Su X; Li P; Han B; Jia H; Liang Q; Wang H; Gu M; Cai J; Li S; Zhou Y; Yi X; Wei W
J Exp Clin Cancer Res; 2021 Jan; 40(1):34. PubMed ID: 33468157
[TBL] [Abstract][Full Text] [Related]
18. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas.
Liu F; Cao J; Wu J; Sullivan K; Shen J; Ryu B; Xu Z; Wei W; Cui R
J Invest Dermatol; 2013 Aug; 133(8):2041-9. PubMed ID: 23344460
[TBL] [Abstract][Full Text] [Related]
19. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.
Prete A; Lo AS; Sadow PM; Bhasin SS; Antonello ZA; Vodopivec DM; Ullas S; Sims JN; Clohessy J; Dvorak AM; Sciuto T; Bhasin M; Murphy-Ullrich JE; Lawler J; Karumanchi SA; Nucera C
Clin Cancer Res; 2018 Dec; 24(23):6078-6097. PubMed ID: 30076136
[TBL] [Abstract][Full Text] [Related]
20. Disulfiram/Cu Kills and Sensitizes
Xie J; Liu J; Zhao M; Li X; Wang Y; Zhao Y; Cao H; Ji M; Chen M; Hou P
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834830
[No Abstract] [Full Text] [Related]
[Next] [New Search]